Nuo Chengjian broke, and the grace of only 13 people rose 70%of the grace?

"Nuo Cheng Jianhua" broke, but Enwei's medicine with only 13 people rose 70%. What is the solution?

Source: Yaozhi.com/智

The concept of innovative medicine has never done the secret recipe of Chinese medicine.

On September 21, Nuo Chenghua, a star innovation pharmaceutical company, was listed on the same day as the old pharmaceutical company Enwei Medicine, but the same start has different endings.

On the morning of the morning, the stock market opened and was highly hoped. Nuo Chengjian, known as the fifth A+H listing in the country, could not escape the fate of the issuance, and fell all the way. As of the time of publication, the decline has reached 16.77%, and the total market value is less than 16 billion yuan. Essence

Picture source: Baidu stock market screenshot

And another main type of specialty (Jieyin), weak R & D strength, only 13 R & D personnel (recommendation reading: only 13 R & D personnel, why is Enwei's medicine listed?), It is reasonable to say that the tradition that is not favored by the industry is not optimistic about the industry. The pharmaceutical company Enwei Medicine rose against the trend with the secret recipe of traditional Chinese medicine, up to 70%.

Picture source: Baidu stock market screenshot

Despite the main reasons that lead to the above differences, there may be the factors of their respective pricing, but in a macro environment that constantly emphasizes medical innovation, such results are indeed puzzling.

Is innovative drugs have become an investor? The reality is that the concept of innovative drugs has not done the secret recipe of Chinese medicine. Is it possible to say Biotech?

Innovative pharmaceutical companies that continue to break

"The Fifth A+H Listing Pharmaceutical Company", "Shi Yigong's endorsement", "the king of cash flow" ... Before Nuocheng Jianhua's innovation board was listed, these labels were endless. Although they were unwilling to admit it, it seemed that everyone was on Looking forward to the situation of Nuo Chengjian can end the situation of BIOTECH today.

After all, with the row of the collection, the capital market "voted with your feet", and the listing of innovative pharmaceutical companies on the one hand has become a common scene, and on the other hand, it has become a big stone that is pressed in the minds of biotech. The first definition of listing is "breaking", that is, "losing money", and some pharmaceutical companies have announced that there are even "unwilling to pay".

For Nuo Chengjian, Nuo Chengjian's stock price in the Hong Kong stock market has shown a cliff -like decline in the past 10 months, which is over the highest point.

60%. Following the Baiji Shenzhou and Maiwei creatures, to some extent, the situation of Nuo Chengjian's opening immediately may have been expected.

Unfortunately, when Nuocheng Jianhua returned A, in order to strengthen the momentum, the action of continuously disclosing the latest news was at least now it seemed that the results were very small.

On September 6, Nuo Chengjian announced that Obitininib had been included in the priority review by CDE for the treatment of recurrence/refractory edge region lymphoma (MZL);

On September 8th, the official website of the China State Drug Administration (CDE) official website was announced that the ICP-248 tablets declared by Nuocheng Jianhua were approved clinically to develop and treat malignant blood tumors;

On September 9th, Nuocheng Jianhua announced that TAFASITAMAB combined with Nicatamine treatment recurrence/refractory diffuse large B -cell lymphoma II registered clinical trial in China to complete the first patient administration in China;

... ...

It is considered how beautiful Nuo Chengjian was listed in Hong Kong in March 2020. The miracle of the market value of 3 times in a short period of time is also worth blowing in the history of the capital market. Endlessly ended, myths no longer.

Of course, breaking is definitely not a manifestation of Nuo Chengjian's Chinese enterprise, but it is more about the overall situation of the industry. Under the analysis, behind the breakthroughs of the pharmaceutical stocks, there are many reasons behind the break on the first day of the listing of Nuocheng Jianhua. Undefeated "high -priced issuance.

Some people admit that in the past, the probability of breaking sufficiently excellent enterprises was actually not large. Most of the broken pharmaceutical companies were still "pseudo -innovation" companies. The biggest feature of these companies was that although the products had some innovative technical points, they were in the market, but they were in the market, but they were in the market. The comparison of products that have been circulating for many years have not changed the essential changes in clinical value. But now the consideration of capital treatment is not only aimed at products and pipelines, but also considering the business, management, follow -up development strategies, business layout, and macro strategic planning of the enterprise.

However, it is precisely because of this that it is not necessarily a bad thing for pharmaceutical companies. At least at present, the frequent breakthroughs of pharmaceutical stocks make Biotech more cautious about listing. Reason is also gradually returning, and the attitude towards innovative medicines is gradually calming down from the fiery. Biotech companies stand out.

The audit system turns into the registration system and who is broken?

In addition, regardless of whether to admit it, the capital market itself is essentially different from the past. The transformation from the audit system to the registration system is a major change in China's capital market. One, who can go public and who can not be listed is no longer the government, but investors. The era of new must be made, and the rest is the fierce market with better risks and income. This is also the fundamental reason why Nuo Chengjian and Enwei Pharmaceutical were listed on the same day, and the ending was unexpected.

It stands to reason that compared to Nuo Chengjian and Enwei's 2021 annual report, whether it is revenue ability and research and development capabilities, Nuo Chengjian is obviously better than Enwei Pharmaceutical, and even for capital that pays more attention to the future incremental market, Nuo Cheng's development potential is better than the latter, but the actual situation is that investors with cups and snake shadows have realized the theme of innovative drugs that have never appeared in the past. It seems more secure. But even so, with the stability of the chaos, the mentality of the mouse taboo device is gentle, and the judgment of the core value of the enterprise will eventually return to the mainstream. After the listing of innovative drug companies in the future, the probability of returning to the polarization of the polarization: companies with innovative ability, research and development capabilities, and strong products will be sought after by investors, and the stock price continues to rise; on the contrary There will be a situation of failure, break, trading volume (market value), and even delisting.

From this point of view, the future fate of Nuo Chengjian and Enwei Medicine seems to be clear at a glance, only to be mature.

There is no cold winter.

Nuocheng Jianhua and Enwei Medicine were listed on the same day. The same start and different endings, what do you think? Welcome to comment and forward for discussion.

- END -